Value of systematic biopsy added to target biopsy for detecting significant cancer in men with Prostate Imaging and Reporting and Data System 5

Taein An, Byung Kwan Park

Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

ABSTRACT

Purpose: To assess the value of systematic biopsy added to target biopsy for detecting significant cancer in men with Prostate Imaging and Reporting and Data System 5 (PI-RADS 5).

Methods: Between March 2014 and November 2018, 186 men had a PI-RADS 5 categorized as an index lesion on magnetic resonance imaging prior to transrectal ultrasound (TRUS)-guided biopsy. Of these patients, 135 (group I) underwent target biopsy alone because of good depiction. The remaining 51 (group II) underwent target and systematic biopsies because of poor depiction. Significant cancer detection rates (CDRs) were compared between the groups. Which type of biopsies contributed to detecting significant cancer was evaluated in the group II.

Results: Significant CDRs of the target biopsy were 67.4% (91/135) in the group I and 47.1% (24/51) in the group II (P=0.0173). However, when systematic biopsy was added to target biopsy, the significant CDR of the group II increased to 52.9% (27/51) (P=0.0900). Of the 27 significant cancers missed by target biopsy in the group II, three were detected by systematic biopsy alone. Moreover, systematic biopsy detected higher Gleason scores in two cases than target biopsy.

Conclusion: Systematic biopsy contributes to detecting additional significant cancers in men with PI-RADS 5 partially visible on TRUS.

Keywords: Biopsy; Magnetic resonance imaging; Male; Prostate; Ultrasonography

INTRODUCTION

Recently, Prostate Imaging and Reporting and Data System version 2 (PI-RADSv2) has been introduced to the clinical practice [1-3]. PI-RADSv2 standardizes the interpretation and reporting of multi-parametric magnetic resonance imaging (MRI) and subsequently enhance communication between radiologists and urologists. But also, it helps to stratify the risk of prostate cancer [1-3]. Many investigators have reported that PI-RADSv2 contributes to detecting significant prostate cancer [4-9].
Systematic biopsy of PI-RADS 5

Prostate Imaging and Reporting and Data System (PI-RADS) 5 is very likely to have significant cancer and thus biopsy is strongly recommended [1-3]. This lesion is larger or more aggressive than that of the other categories so that it is clearly seen on MRI. Frequently, target biopsy alone is enough to detect significant cancer [1-3]. However, the likelihood of significant cancer is not 0% even though the other prostate is categorized as PI-RADS 1, in which the multiparametric magnetic resonance (MR) features are unremarkable. Moreover, PI-RADS 5 does not guarantee significant cancer detection 100%. Therefore, it is still unclear if addition of systematic biopsy to target biopsy is necessary in detecting significant cancer. Our hypothesis was that systematic biopsy provides additional value to target biopsy for detection of significant cancer in men with PI-RADS 5.

The purpose of our study was to assess the value of systematic biopsy added to target biopsy for detecting significant cancer in men with PI-RADS 5.

METHODS

Patient selection

Between March 2014 and November 2018, 850 men underwent prostate biopsy, which was performed by a single radiologist with 16-year experience of genitourinary intervention (Fig. 1). Among these patients, 664 were excluded due to PI-RADS 1–4 lesions (n=621), low (<2.5 ng/mL) prostate specific antigen (PSA; n=20), previous treatments (n=14), no pre-biopsy MRI (n=5), transperineal biopsy (n=2), poor quality MRI images (n=1), and metastatic prostate cancer (n=1).

The remaining 186 men (median, 68 years; range, 35 to 86) met for the following inclusion criteria: high (≥2.5 ng/mL) PSA, PI-RADS 5 lesion, pre-biopsy MRI, and transrectal ultrasound (TRUS)-guided biopsy. Their PSA, prostate volume, PSA density, MRI-biopsy interval, and tumor size ranged 2.54 to 2,564.38 ng/mL (median, 7.22), 13 to 203 mL (median, 35), 0.05 to 68.6 ng/mL² (median, 0.20), 0 to 397 days (median, 31), and 15 to 57 mm (median, 19), respectively. These patients were divided into group I (n=135) and group II (n=51). The group I had 135 PI-RADS 5 lesions which were completely visible on TRUS. The group II had 51 PI-RADS 5 lesions which were partially visible on TRUS. Patient demographics in each group were summarized in the Table 1.

Prostate MRI and biopsy

Prior to prostate biopsy, multi-parametric MRI was scanned to obtain the following sequences: T2-weighted, diffusion-weighted, and dynamic contrast-enhanced axial MR im-
A single radiologist interpreted MR images and then performed target and/or systematic biopsy under TRUS guidance. He was already familiar with the following TRUS techniques and imaging features: (1) prostate was not compressed for lesion detection by a probe, (2) a TRUS lesion was located higher than an MRI lesion, and (3) a significant cancer appeared hypoechoic in peripheral zone and hyperechoic in transition zone. Group I underwent target biopsy alone because their PI-RADS 5 lesions were completely visible on TRUS. In the group II, systematic biopsy was added to target biopsy because their PI-RADS 5 lesions were partially visible on TRUS (Fig. 2). This biopsy was performed to systematically sample cores where PI-RADS 4 was not located.

Data analysis
MRI images before 2015 were reloaded into Picture Archiving and Communication System (PACS) to review and to categorize prostate lesions with PI-RADSv2. Since 2015, when PI-RADSv2 was released, the original PI-RADS scores categorized by a single radiologist prior to biopsy were used for analysis.

Overall cancer detection rate (CDR) was calculated by the number of cancer cases divided by the number of biopsy cases in each group or each biopsy. Significant cancer was defined as one with Gleason score (GS) ≥ 7. Significant CDR was calculated by the number of GS ≥ 7 cases divided by the number of biopsy cases in each group or each biopsy. Overall and significant CDRs were compared between the groups or between the biopsies.

Positive core rate (PCR) was calculated by the number of cancer cores divided by the number of biopsy cores. PCR was compared between the groups or between the target biopsies. PCR was also compared between the target and systematic biopsies in the group II.

The size of peripheral PI-RADS 5 was measured at diffusion-weighted axial images and that of transition PI-RADS 5 was measured at T2-weighted axial MR images. When PI-RADS 5 involved both, the tumor size was measured at diffusion-weighted or T2-weighted MR images depending on which zone it was located more dominantly. The median number of total or cancer cores were compared between the groups and between the biopsies.

The medians of the greatest GS (top GS) were compared.

Table 1. Patient demographics

<table>
<thead>
<tr>
<th>Demographic</th>
<th>PI-RADS 5 cases (n=186)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group I (n=135)</td>
<td>Group II (n=51)</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>68 (35–87)</td>
<td>69 (51–86)</td>
</tr>
<tr>
<td>PSA (ng/mL)</td>
<td>7.3 (2.5–2,783.6)</td>
<td>7.2 (2.9–52.5)</td>
</tr>
<tr>
<td>Prostate volume (mL)</td>
<td>33 (13–203)</td>
<td>42 (19–304)</td>
</tr>
<tr>
<td>PSAD (ng/mL²)</td>
<td>0.23 (0.05–108.73)</td>
<td>0.18 (0.05–2.78)</td>
</tr>
<tr>
<td>MRI-biopsy interval (day)</td>
<td>27 (0–397)</td>
<td>39 (0–308)</td>
</tr>
</tbody>
</table>

Values are presented as median (range).

PI-RADS, Prostate Imaging Reporting and Data System; PSA, prostate specific antigen; PSAD, prostate specific antigen density; MRI, magnetic resonance imaging.
between the groups. Percentage length of top GS core was defined as the proportion of cancer length compared to the entire length of a biopsy core. The percentage length was also compared between the groups when targeting biopsy was performed.

Which type of biopsies contributed to detecting insignificant or significant cancer was evaluated in the group II. GSs were compared between target and systematic biopsies to determine how many systematic biopsies achieved higher GS than target biopsy.

**Statistical analysis**

Mann-Whitney test was used to compare patient age, PSA, prostate volume, PSA density, MRI-biopsy interval, tumor size, top GS, and percentage length of significant cancer core between the groups. Fisher’s exact test was used to compare CDRs and PCRs between the groups or the biopsies. Odds ratio (OR) was obtained to quantify the strength of the association between the biopsies in targeting PI-RADS 5 completely or partially visible on TRUS. The approximation of Woolf was used to calculate 95% confidence interval. Wilcoxon matched-pairs signed-ranks test was used to compare cores between target and systematic biopsies in the group II. Commercially available software (PASW Statistics, version 20.0; IBM Co., Armonk, NY, USA) was used for statistical analysis. A two-side P-value of less than 0.05 was considered statistically significant.

**Ethical statement**

This retrospective study was approved by Institutional Review Board of Samsung Medical Center (IRB number: 2019-01-068) and informed consent was waived.

**RESULTS**

Group I had smaller prostate volume (P=0.0263), higher PSA density (P=0.0141), and shorter MRI-biopsy interval (P=0.0049) than group II (Table 1). There was no difference between the groups in terms of age (P=0.7187) and PSA (P=0.3935).

The overall CDRs of the target biopsy were 82.2 (111/135) in the group I and 60.8 (31/51) in the group II (P=0.0035 and OR=2.984) (Table 2). The significant CDRs of the target biopsy were 71.2 (532/747) in the group I and 48.1 (143/297) in the group II (P<0.0001 and OR=2.665).

However, when the outcomes of systematic biopsy were added to those of target biopsy in the group II, there was no difference between group I and II in terms of overall CDR (P=0.0734 and OR=2.030) and significant CDR (P=0.0900 and OR=1.798). Still, the PCR of the group I was much higher than that of the group II (P<0.0001 and OR=5.541) (Table 3).

The median tumor sizes were 20 mm (range, 15 to 57) in the group I and 18 mm (range, 15 to 50) in the group II (P=0.1268) (Table 4). Target biopsy yielded a greater number of median cancer cores in the group I than group II (P=0.0303) although the number of target biopsy cores was smaller in the former than the latter (P=0.0345). There was no difference between group I and II in terms of top GS (P=0.0993) and percentage

---

**Table 2. Comparison of target biopsy outcomes according to the lesion visibility on TRUS**

<table>
<thead>
<tr>
<th>Biopsy outcome</th>
<th>TRUS-guided target biopsy (n=186)</th>
<th>OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall CDR (%)</td>
<td>Group I (n=135)</td>
<td>82.2 (111/135)</td>
<td>60.8 (31/51)</td>
</tr>
<tr>
<td>Significant CDR (%)</td>
<td>67.4 (91/135)</td>
<td>47.1 (24/51)</td>
<td>2.327 (1.206–4.490)</td>
</tr>
<tr>
<td>PCR (%)</td>
<td>71.2 (532/747)</td>
<td>48.1 (143/297)</td>
<td>2.665 (2.019–3.517)</td>
</tr>
</tbody>
</table>

TRUS, transrectal ultrasound; OR, odds ratio; CI, confidence interval; CDR, cancer detection rate; PCR, positive core rate.

**Table 3. Comparison of biopsy outcomes between group I (target) and II (target+systematic)**

<table>
<thead>
<tr>
<th>Biopsy outcome</th>
<th>TRUS-guided biopsy (n=186)</th>
<th>OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall CDR (%)</td>
<td>Group I (n=135)</td>
<td>82.2 (111/135)</td>
<td>68.6 (35/51)</td>
</tr>
<tr>
<td>Significant CDR (%)</td>
<td>67.4 (91/135)</td>
<td>52.9 (27/51)</td>
<td>1.798 (0.9329–3.463)</td>
</tr>
<tr>
<td>PCR (%)</td>
<td>71.2 (532/747)</td>
<td>30.9 (188/609)</td>
<td>5.541 (4.386–7.001)</td>
</tr>
</tbody>
</table>

TRUS, transrectal ultrasound; OR, odds ratio; CI, confidence interval; CDR, cancer detection rate; PCR, positive core rate.
Table 4. Comparison of group I and II in terms of lesion size and biopsy features

<table>
<thead>
<tr>
<th>Lesion size and biopsy features</th>
<th>PI-RADS 5 (n=186)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group I (n=136)</td>
<td>Group II (n=128)</td>
</tr>
<tr>
<td>Tumor size (mm)</td>
<td>20 (15–57)</td>
<td>18 (15–50)</td>
</tr>
<tr>
<td>No. of target cores</td>
<td>5 (2–12)</td>
<td>6 (1–10)</td>
</tr>
<tr>
<td>No. of target cancer cores</td>
<td>4 (0–12)</td>
<td>3 (0–8)</td>
</tr>
<tr>
<td>Top GS(^a)</td>
<td>7 (6–9)</td>
<td>7 (6–8)</td>
</tr>
<tr>
<td>% length of top GS core</td>
<td>70 (5–100)</td>
<td>70 (5–95)</td>
</tr>
</tbody>
</table>

Values are presented as median (range). PI-RADS, Prostate Imaging Reporting and Data System; GS, Gleason score.
\(^a\)Top GS and % length of top GS core obtained from target biopsy were compared between the groups.

In the group II, overall CDRs of target and systematic biopsies were 60.8 (31/51) and 47.1 (24/51) (P=0.2332 and OR=1.744) (Table 5). However, the significant CDRs of these biopsies were 47.1 (24/51) and 23.5 (12/51) (P=0.0220 and OR=2.889). The PCRs of these biopsies were 48.1 (143/297) and 14.4 (45/312) (P<0.0001 and OR=5.510). The number of cores were 297 (median, 6; range, 1 to 10) in the target biopsy and 312 (median, 6; range, 3 to 12) in the systematic biopsy (P>0.9999).

Of the 31 cancer cases, the number of cancer cores were 143 (median, 5; range, 1 to 8) in the target biopsy and 40 (median, 1; range, 0 to 5) in the systematic biopsy (P<0.0001).

Of the 27 significant cancers in the group II, 15 were detected by target biopsy, nine by target and systematic biopsies, and three by systematic biopsy. Of the three significant cancers detected by systematic biopsy alone, two and one were diagnosed as GS 6 tumors and a benign tissue by target biopsy, respectively (Fig. 2). One GS 7 (3+4) tumor was diagnosed by target biopsy, whereas it was confirmed as a GS 8 (4+4) tumor by systematic biopsy.

**DISCUSSION**

MRI-TRUS fusion or in-bore MRI-guided biopsy targets PI-RADS 5 because significant cancer is very likely to be present [1-3]. When the other prostate tissue except PI-RADS 5 is PI-RADS 1 or 2, additional target biopsy is not so effective because of low CDRs. Several investigations have reported that the CDRs of biopsy in PI-RADS 1 or 2 range from 14% to 25% [4,6,8,10]. PI-RADSv2 definitely recommends a biopsy in the PI-RADS 5 cases but does not show how to do it. Still, urologists or radiologists do not know that systematic biopsy helps additional detection of significant cancer if it is combined with target biopsy. Simply increasing the number of cores also run the higher risk of biopsy-related complications such as pain, urinary retention, bleeding, or infection [11-14].

If only a few cores detect significant cancer, target biopsy alone is ideal for correct diagnosis and rare complications. The significant CDR of the target biopsy in the group I is not inferior to those in previously reported papers using MRI-TRUS fusion or in-bore MRI-guided biopsy. They have showed that their CDRs ranged from 62% to 85% in PI-RADS 5 [8,10,15,16]. However, PI-RADS 1 or 2 does not have significant cancer 100% even though this category is very unlikely or unlikely to have it [1-3]. Moreover, because various kinds of inflammation can mimic prostate cancer, significant cancer cannot be detected if target biopsy alone is performed [17-19].

Our study demonstrated that systematic biopsy detected additional significant cancers in the PI-RADS 1 or 2, although target biopsy did not find significant cancer in the PI-RADS 5. When PI-RADS 5 was completely visible on TRUS (group I), the CDR of the target biopsy was better than that of the target biopsy in PI-RADS 5 which was partially visible on TRUS (group II). Accordingly, lesion visibility on TRUS may influence the detection of significant cancer. These findings suggest that systematic biopsy is necessary if PI-RADS 5 does not appear completely visible on TRUS.

Our study showed another evidence that systematic biop-
Systematic biopsy of PI-RADS 5

Systematic biopsy is necessary. The overall and significant CDRs of the target biopsy in the group I were statistically different from those of the target biopsy in the group II. However, after systematic biopsy was added to target biopsy in the group II, the overall and significant CDRs were elevated so that group II were not different from group I in terms of CDR. The overall and significant CDRs in the group II became higher 6% to 9% by systematic biopsy added to target biopsy. During the in-bore MRI-guidance, target biopsy is preferred to use, whereas systematic biopsy is hard to perform because it is considered time-consuming and inefficient procedures for detecting significant cancer in the PI-RADS 5 cases. From this point of view, in-bore MRI-guided biopsy might be inferior to MRI-TRUS fusion biopsy using both target and systematic biopsy. Venderink et al. [16] have reported that there was no difference between the two types of biopsy techniques. A systematic review also shows that in-bore MRI-guided biopsy is not different from MRI-TRUS fusion in terms of overall and significant CDRs [20]. However, these studies did not compare in-bore MRI-guided target biopsy and MRI-TRUS fusion target and systematic biopsies.

There are other reasons for necessity of systematic biopsy in the PI-RADS 5 cases. First, prostate cancer is more likely to be multifocal in the PI-RADS 5 compared to the other categories. Multifocal significant cancers are frequently encountered in the post-prostatectomy specimens [21-23]. Systematic biopsy may detect so small significant cancers which are hard to find on MRI. Second, it is not uncommon that a small lesion may have higher GS than a large lesion. Our study showed that the GSs of two cases were upgraded in the systematic biopsy than in the target biopsy. Third, it should be kept in mind that PI-RADS 5 may not be targeted. Even if the TRUS guideline of target biopsy is placed in the lesion center, the biopsy needle may be shot somewhat off the center. Therefore, one or two biopsy cores may be insufficient to reveal the small component of GS 4 or 5. Our study showed that the median number of target cores were 5 in complete visible PI-RADS 5 on TRUS. Still, the optimal number of target cores is unclear and further investigation is necessary.

Our study had some limitations. First, the CDR of target biopsy in the group I can be underestimated because systematic biopsy was not performed. Even though PI-RADS 5 is completely visible, the necessity of systematic biopsy should be evaluated. Second, what systematic protocol is optimal for PI-RADS 5 is still unknown. It requires maximizing CDR and minimizing complications. Third, what number of target cores is ideal is still unknown. If the component of GS 4 or 5 is small and eccentric, significant cancer cannot be detected with only one or two target cores. Fourth, transition PI-RADS 5 was not evaluated because of a relatively small number of cases. Last, the design of our study was retrospective.

In conclusion, TRUS-guided target biopsy provides higher overall and significant CDRs in the completely visible PI-RADS 5 than partially visible PI-RADS 5. However, systematic biopsy has a potential to detect additional significant cancers in the other prostate when target biopsy does not sample significant cancer from the partially visible PI-RADS 5 on TRUS. Therefore, systematic biopsy as well as target biopsy is recommended in the PI-RADS 5 cases.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ORCID

Taein An https://orcid.org/0000-0002-0569-6022
Byung Kwan Park https://orcid.org/0000-0002-4114-8859

AUTHOR CONTRIBUTIONS

Conception or design: BKP.
Acquisition, analysis, or interpretation of data: TA, BKP.
Drafting the work or revising: TA, BKP.
Final approval of the manuscript: TA, BKP.

REFERENCES

5. Hofbauer SL, Maxeiner A, Kittner B, Heckmann R, Rei-


